Why is $SPRY moving today? · SEC 8-K archive

$SPRY SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $SPRY: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $SPRY filing catalyst

Why did $SPRY trigger an AI stock catalyst alert?

$SPRY triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.0/10). Headline: ARS Pharmaceuticals Reports Q3 Revenue of $37.7M, Net Loss Decreases to $(0.36) EPS. Key points: - Total Q3 revenue reached $37.7M, driven by $33.4M in U.S. net product sales for neffy. - Net loss narrowed to $35.6M ($(0.36)/share) compared to $51.2M ($(0.52)/share) in prior-year quarter. - SG&A expenses reduced, company reaffirmed targeted cash flow breakeven timeline by end of 2027.

How did $SPRY stock react after the SEC filing?

After the SEC 8-K for $SPRY, observed market reaction: T0 price $2.65. Past moves do not guarantee future results.

Where can I get real-time $SPRY SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $SPRY via Telegram and the VIP Web Terminal from €10/month.

$SPRY

$SPRY – ARS Pharmaceuticals Reports Q3 Revenue of $37.7M, Net Loss Decreases to $(0.36) EPS

ARS Pharmaceuticals, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $SPRY

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.0 / 10)

Total Q3 revenue reached $37.7M, driven by $33.4M in U.S. net product sales for neffy.
Net loss narrowed to $35.6M ($(0.36)/share) compared to $51.2M ($(0.52)/share) in prior-year quarter.
SG&A expenses reduced, company reaffirmed targeted cash flow breakeven timeline by end of 2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →